SCHEMBL283683

SCHEMBL283683

CCN(CC)C(=O)c1ccc(C)c([N+](=O)[O-])c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.62
HPGD P15428 5/20 0.59
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
GAA P10253 3/20 0.55
HTT P42858 1/20 0.55
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
PKM P14618 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 1/20 0.50
HCAR3 P49019 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MAPT P10636 1/20 0.49
POLB P06746 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639329 0.88 TSHR (0.59) TSHRHPGDCES2CES1GAA
SCHEMBL14314759 0.88 TSHR (0.62) TSHRHPGDGAAALDH1A1SMN1; SMN2
SCHEMBL9188252 0.88 CASP6 (0.57) HPGDALDH1A1SMN1; SMN2LMNAHCAR3
SCHEMBL4464468 0.84 HCAR3 (0.49) HPGDALDH1A1SMN1; SMN2LMNAHCAR3
SCHEMBL14459959 0.83 TSHR (0.56) TSHRHPGDCES2CES1GAA
SCHEMBL5914014 0.83 TSHR (0.68) TSHRCES2CES1GAAHTT
SCHEMBL15989292 0.81 HCAR3 (0.50) HPGDHTTALDH1A1SMN1; SMN2MEN1
SCHEMBL5591787 0.81 HCAR3 (0.65) HTTALDH1A1SMN1; SMN2PKMKMT2A
SCHEMBL10013755 0.81 CYP1A2 (0.59) TSHRHPGDALDH1A1SMN1; SMN2MEN1
SCHEMBL1298401 0.81 HSP90AA1 (0.48) HPGDALDH1A1SMN1; SMN2LMNAHCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-2428508-B9 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2016-04-20 EP disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
CN-102421761-B Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC 2014-06-18 CN disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 TSHR 3964/4885HPGD 4520/4885CES2 3487/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 TSHR 3964/4885HPGD 4520/4885CES2 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.